Physician profile
Melissa Lepine
NPI 1275973273
$2,384.72
in general payments reported to CMS, 2019-2025
19 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.27 · 2023: $389 · 2024: $913 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,370.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $270.10 | 2023-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $251.27 | 2024 | Voquezna |
| Neurelis, INC. | $221.33 | 2023-2024 | Valtoco |
| Lilly USA, LLC | $186.11 | 2024-2025 | Zepbound |
| Dexcom, INC. | $150.00 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Janssen Biotech, INC. | $146.19 | 2025 | |
| Amgen INC. | $135.00 | 2025 | Krystexxa |
| Kyowa Kirin, INC. | $118.37 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $112.56 | 2024 | Dupixent |
| Novo Nordisk INC | $111.03 | 2023 | |
| Neurocrine Biosciences, INC. | $103.71 | 2025 | |
| Tris Pharma INC | $101.62 | 2024 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $97.46 | 2024 | |
| Edwards Lifesciences Corporation | $87.72 | 2025 | |
| Janssen Pharmaceuticals, INC | $85.43 | 2025 | Spravato |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $75.34 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.96 | 2023 | |
| Medtronic, INC. | $54.25 | 2024 | Interstim |
| Abbvie INC. | $14.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Lepine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.